Oncology Medical News about Neoplasms Pain Hydromorphone

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The Role of OROS Hydromorphone in the Management of Cancer Pain
Pain Practice, 10/27/09

Gardner–Nix J et al. – This review surveys the available literature on the only available once–daily sustained–release formulation of hydromorphone, and its use in cancer pain management. Sustained–release (SR) formulations have a more consistent opioid plasma concentration, thereby minimizing the peaks and troughs associated with immediate–release opioid formulations. OROS hydromorphone (Jurnista, Janssen Pharmaceuticals, NV, Beerse, Belgium) releases hydromorphone over a 24–hour dosing period. Studies comparing its efficacy with other opioids such as morphine and oxycodone found comparable results overall. Recent trials have provided evidence of decreased rescue medication use for breakthrough pain, a good safety profile, and quality of life benefits. It appears to be an efficacious and well–tolerated treatment. The pharmacokinetics of OROS hydromorphone are linear and dose–proportional, and only minimally affected by the presence or absence of food. In addition, the SR properties of OROS hydromorphone are maintained in the presence of alcohol, with no dose dumping of hydromorphone.

<< Previous
Interventions for central giant cell granuloma (CGCG) of the jaws

Next >>
Living with mesothelioma. A literature review

An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS hydromorphone in patients with chronic cancer pain
BMC Palliative Care, 10/16/09 Relevance Score: 81%

Core Aspects of Satisfaction with Pain Management: Cancer Patients' Perspectives
Journal of Pain and Symptom Management, 11/02/09 Relevance Score: 68%

Outpatient Continuous Interscalene Brachial Plexus Block in Cancer-Related Pain
Journal of Pain and Symptom Management, 11/03/09 Relevance Score: 67%

Global perspectives on cancer pain
Pain Research and Management, 10/27/09 Relevance Score: 67%

A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial
Current Medical Research and Opinion, 10/08/09 Relevance Score: 67%